$6.15
$5.77
$12.07
$5.83
$779.9M
-14.71%
This is a preview of the full version of Prosperse
Relay Therapeutics, a biotech company developing oncology treatments, announced a secondary share offering of 28.6 million shares at $7 per share, which is seen as highly dilutive to existing shareholders. The stock fell nearly 14% in response, while the broader market gained over 1%.
Eric Volkman
Sep 11, 2024
Relay Therapeutics, a clinical-stage precision medicine company, announced the pricing of a $200 million public offering of its common stock. The offering is expected to close on September 12, 2024.
N/A
Sep 11, 2024
Date: Oct 25, 2024
Date: Oct 25, 2024
Date: Oct 25, 2024
Date: Oct 24, 2024
Date: Oct 24, 2024